Granted FDA breakthrough status for adults who received a prior treatment for HER2+ Metastatic Breast Cancer (mBC). Photo of woman in confident pose: With ENHERTU, I stand determined. Granted FDA breakthrough status for adults who received a prior treatment for HER2+ Metastatic Breast Cancer (mBC). Photo of woman in confident pose: With ENHERTU, I stand determined. Granted FDA breakthrough status for adults who received a prior treatment for HER2+ Metastatic Breast Cancer (mBC). Photo of woman in confident pose: With ENHERTU, I stand determined.
Not an actual patient.

What is ENHERTU?

ENHERTU (en-HER-too) is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive:

  • Breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
    • for metastatic disease, or
    • have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
  • Stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
  • It is not known if ENHERTU is safe and effective in children.

What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death.

If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms.

Potential risks of
treatment with ENHERTU

SEE SAFETY INFORMATION

Treatment access and
downloadable resources

LEARN ABOUT ENHERTU4U